Vapogenix is developing a suite of products to treat localized pain using formulated volatile anesthetics.
AWARD (A Wound Analgesic with RapiD action)
Severe pain from acute and chronic wounds is common, yet poorly managed. Current treatment options are often inadequate, and frequently result in intolerable systemic side effects.
Vapogenix is developing volatile anesthetic formulations for topical application to wounds, to reduce wound pain at rest and during wound care procedures. Preliminary data show that topical application of volatile anesthetics results in rapid and long-lasting pain relief.
We are currently conducting a Phase II clinical trial in Australia, in patients with painful wounds.
RAFT (Rapid Analgesic For Topical use on Intact Skin)
The RAFT project goal is to develop a rapidly-acting topical analgesic for use on intact skin to alleviate pain acute procedural pain such as that associated with venipuncture, venous cannulation and minor dermatological procedures. Most of the currently available options require long application times, ranging from 20 minutes to 60 minutes. There is a huge unmet need for a rapidly-acting and effective topical analgesic, particularly for children and needle-phobic adults. We have completed a Phase I clinical study that demonstrated a promising safety and tolerability profile of our products.
TAIM (Topical Analgesic for Inflammatory & Muscular pain)
Inflammation is associated with many acute and chronic painful conditions, such as arthritis, gout and muscle pain. Much of the pain associated with these conditions is due to the release of pain-inducing mediators from white blood cells at the site of inflammation. Some volatile anesthetics have anti-inflammatory effects, in addition to their analgesic properties, and therefore have the potential to be highly effective in painful inflammatory conditions. The first TAIM product is designed to have a dual benefit, combining these analgesic and anti-inflammatory effects in a topical product.